The application relates to a conjugate comprising interleukin 22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis such as the ED A isoform of fibronectin. In particular the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder such as autoimmune diseases including inflammatory bowel disease (IBD).